Sigrid

What They Do

Non-systemic metabolic health platform using proprietary SiPore® technology. Targets metabolic health at the gut level without systemic drug exposure. Expanding into oral care via exclusive global partnership.

Funding

Valuation: Not disclosed. $5M raised (2024) to accelerate US growth. Investors: Not disclosed.

Traction

• Successful US pilot program
• Exclusive global partnership to commercialize SiPore® in oral care
• Expanding US physician channel

See Also

• Sweden
• Preventive Health